{"name":"PharmAbcine","slug":"pharmabcine","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tanibirumab","genericName":"Tanibirumab","slug":"tanibirumab","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Tanibirumab","genericName":"Tanibirumab","slug":"tanibirumab","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOZHlRSFZJaFFCNGpHOGFacmc5REYyTXdfLUNCRTdKbnFXbVcxLWJUNU96V09LeDZtaHdfbzhLZDVxVkZQQVM5VFkxZmVqck9ZejhXSk8yVFczSXhRV1M4cXhJQm9CSnBKVmdfbUViUVhyTk5MdEsxT1JVQm5UT0VmUtIBlAFBVV95cUxPaWc2V05KSGpyZF8wUEZMcUVpSS1EekVFbkxxaFMyRVVSNGRKY21jdGVCY2JKbnRSaHpCSWE4RFRtWDFsUEpNMGg1am1FRVhDV216bFpURUZ4QUtCTk9SM2FuLXA0WjRmel8wU0VhWU1XS0RUUFUwbVg0YzhNSzVlRXRVMGk1N0tNcExaRHJ6THFOcF95?oc=5","date":"2026-01-10","type":"deal","source":"Chosunbiz","summary":"Korean pharma and biotech firms relocate offices to boost R&D collaboration - CHOSUNBIZ - Chosunbiz","headline":"Korean pharma and biotech firms relocate offices to boost R&D collaboration - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9MZEVqUjNxNDctdXdKaW9RVWlacXlCRHlKeURaMGRLdl81bTBTR1ZERGRvOEFwUlJFb0hZam5CcERIZkJrZzNmNXJKUVFXa2dVSkJwendUejJHZ01tT2llbHZXWkhkY3h4RkxGSzdB0gFyQVVfeXFMT290cEVUMGh2ODdsTFcwZGo3SVBBNzVod3hWMEdueGc2Qm5sNmJqR0dya3BRcnVqcFotS04wWWQxQy1QQUhzVzZ1RG9paXlZQ0NJeXJMVzNxbkxVaDM2TC1rRGtabmNkaFZTbU5Ma01XellB?oc=5","date":"2025-05-28","type":"pipeline","source":"koreabiomed.com","summary":"PharmAbcine to be delisted from Kosdaq amid financial and pipeline collapse - koreabiomed.com","headline":"PharmAbcine to be delisted from Kosdaq amid financial and pipeline collapse","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOWHhkMWlNT1M4V2VUUmxtMy1fdklaMU9iNlRvUUZEbTZaRndHOTAzbTNxUUQxT2NHOEk5aWpITXJkelN6cld6NEtkeWJvUTFET01QdERZZE5lRkF5VEgyWXkxaU9XNURsSXFzZEwyQnR3N1RVMWlSX1ZPVUUzbE9LadIBlAFBVV95cUxOc21xX2JQc0p1dkN1azhvb3pzOGQwZnVRNjhTOTByZGJEX0hKNXdBZkNWMkZqS0RnRlZYRXQ0UTBPRTd5RURjNEJ4SEN2OUpCWXJlWjVSVkYzLVptUHI2R3dkTFUxUnVxUkRaNU5VTmYwNFozbExPRUJzN1AwNGlBcU1mUE1JZjB1eS1zZTJxSE5qczZV?oc=5","date":"2025-05-28","type":"trial","source":"Chosunbiz","summary":"PharmAbcine faces delisting from KOSDAQ due to financial struggles and halted trials - CHOSUNBIZ - Chosunbiz","headline":"PharmAbcine faces delisting from KOSDAQ due to financial struggles and halted trials - CHOSUNBIZ","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5qUlhFQUFrTnNjYmFPaFRHbWVIaWJzYlRDYWRfdVRvMGhuSXl3eEQ5OFZPcDFLTV9yRldvbVF1Zm04QjItLXBnYzlOZWZrUTk1TlF3alJSN2ZncGFPSDVEMHl1N2c5dEwxRUpXR2930gFyQVVfeXFMTU9QQkt0aWN2cnA1UnY5WkVFNmdhZmxsN3hYcXBDdE9sYWp1cDBuWWdYWkMyNGVtMUFrb3ZBM3pNb25lTFFqMHB2c1o0V3BZczRXT2pQTURvWFhFUlJqYVdpVEdTblc5aFdBaFJqVzg4VVZB?oc=5","date":"2024-07-25","type":"pipeline","source":"koreabiomed.com","summary":"PharmAbcine to be delisted from Kosdaq amid financial and operational struggles - koreabiomed.com","headline":"PharmAbcine to be delisted from Kosdaq amid financial and operational struggles","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQVm1yTFFpSnlTZk9VbWZXcVRBSENTRllIbUtobkJUV0dzclhwYjFuUGQ5Yy14ZllWZlk2SW4zTzJMSUZTVG9YaWlyRDY4OTJ0ZVh6TVVGX0xDWGVSYjhhQ2ZKTVBDbjc1M09PdEpEakxtVkVPeEQ5eHl4aGFhMHhac3NkQzR1ZXpmRmhLNlVkUlZwUFRrSHFJUTZwZ1pSMURFdmNNV0hVSWc2UnMwTktrbVBhZXg3RjRlejRxREdib295OU9lWWR3bmczaVo?oc=5","date":"2024-07-02","type":"trial","source":"BioPharma APAC","summary":"South Korea's PharmAbcine Advances Novel nAMD Treatment PMC-403 to Key Phase 1 Milestones - BioPharma APAC","headline":"South Korea's PharmAbcine Advances Novel nAMD Treatment PMC-403 to Key Phase 1 Milestones","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxOdkU2MjZfUVFueXp0Z0JnUldNaFB5MWxxY3NZeHF1dXYwb0tMVGg1VXkyZUhLWmlyMUx3RXE5SEp6UUg2RGRFSXRkSHR5S1BYdWJ6SEZQRG9DbUdxcnlMcTUzbnlrMUVublgyTXV2MjZlRU5Rd2VEWEVaSkZvRnhHY2M2TVktN2p3eE4xaG53VnpreEViTGhfZFNQc0FXanMybm8yQjc5T0RCT1FLYmZMc3ZFMkIyY3RleGFHSDZoWWNsbVZpZ05WY0F2UjdLbVc5OXU2TG81RF9RN2RodllPRWp3OWN5NDc3emw4VnBNWFZTTEs3dzZOSzBLVlA3Q2dBV0tHNk9BMGNLU3l4eDUtRnJHZy1kQ1I4dGR2d0c4QmM3Y2R3RTBFdGxSaXBiZHJZc3c1QUZnYw?oc=5","date":"2024-07-01","type":"trial","source":"prnewswire.com","summary":"PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg - prnewswire.com","headline":"PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNMzRBbGE2d3RCN0dEdnRYZ1BMSjB4R3lMMkIxcUJGMVp2b1ZUbjNPdmlBc3RxMzc5ajRFZ1VOTG1ieGp0TzBldlBVWGotQTJBOXM5UExrUjBOVFVFNkxUemlNVy1raHBJMFd2ajRCX3RQc29kN1V1bUhoSTgwa21MSUJuWlhYd0xiazVjWXFOZGo1RlZRangydnhfUmJxY0pFMUEyZ0w3bWhrOWhYelNOZHpUaDhGLUpIMGczZERBazQtU2t6OHU5S28ybGwyUFprM1Q3eTZzM3gyckdjZndVUFU1MC1jTkt6SnNWSG5ZNVJuUU9pUVM4Q1ppYV96dEVWYjJ5RzFQdWJaampCa3h5a2E1dw?oc=5","date":"2024-05-22","type":"trial","source":"prnewswire.com","summary":"PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024 - prnewswire.com","headline":"PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platfor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOb0lwZnpDcXpUenZreTJEQ0QyR281SkpUTkpoV3gxTmdNVDBZQ1NzNksyNU5wbmE4ajE0NWhtSk5zU2NES0RIQlp0V0M0TWFHeHZVbXNkYlQ5NGxENGRtR1IwMF96MmFuaFgtVE56aGtQUzJjaDBVcXZ4TmFDaWpyREFqeng0aDVLWlA5ZzZJNEN3T0FSb1JWYlEyOGViajhIWkdMRjVYMlB4Zm1XMGhfenkzOHgxYXREUzNRQUlKYXFWZEZ5RTc2VUR5N3FaaDBpckE?oc=5","date":"2023-11-23","type":"pipeline","source":"BioPharma APAC","summary":"PharmAbcine Reveals PMC-403 Potential in Idiopathic Systemic Capillary Leak Syndrome Models - BioPharma APAC","headline":"PharmAbcine Reveals PMC-403 Potential in Idiopathic Systemic Capillary Leak Syndrome Models","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9ycnRkZVZ1MzJvakJfT0M2U0F5X3BDbGY5eW9VOG1wLUVsRVR5cVc3VzYwS0U1Vkx0NjFMcW1VTDByNW5EY2FRXy1kaHdZRlJabU1hTU1SbjV3SlRoZzkwd19DSVdxbVhtVHY5OEl30gFyQVVfeXFMT1FPQnhDZ042LVA2b1lQaVpZUHRBVmZSOGE2SkFneXF1NHBEU2U0WlNNZ3V4anloZWNsUHlGWFNkdVVxeEtTdTFhUUJpbzF1cUZMeGNyeVJ0Y1pib2ZqQWxOQkliYjVNRjU4TnlmM3h6N2F3?oc=5","date":"2021-06-28","type":"pipeline","source":"koreabiomed.com","summary":"Korean drug pipelines illuminated at global biotech convention - koreabiomed.com","headline":"Korean drug pipelines illuminated at global biotech convention","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5UazlnUEI5UENVb0RvTXRhdVZ5U2pZOC1oMnB6U2VlY3lfM0R3NldCZnItYnR4Q29MSmFpZGt3SXR4Sm00QmRaLUx5bHhvMDNMNkExejZMeTFiZFdyX0U5c2VuV05MZjBkSHE0UXVB0gFyQVVfeXFMUFRTUGt6djNXU1BUQThNMTJ6S3lZZmxCc2J5NFh3c1ZzMlJ4MGZRUjhWalBfZDJYcjcyM0lfUmhoNEk3emhkUFEzSnBIRGZJUTI1REI4dDBPQWdGSFFnN0FBdXNVU2dobjNLZFloMU5VUGFn?oc=5","date":"2021-01-08","type":"pipeline","source":"koreabiomed.com","summary":"Korean drugmakers to present strategies at annual JP Morgan Healthcare Conference - koreabiomed.com","headline":"Korean drugmakers to present strategies at annual JP Morgan Healthcare Conference","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}